FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

3187211000001106: Seretide 250 Accuhaler (GlaxoSmithKline) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 01-May 2006. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
17351101000001116 Seretide 250 Accuhaler (GlaxoSmithKline) (product) en Fully specified name Active Only initial character case insensitive SNOMED CT United Kingdom drug extension module
58227401000001114 Seretide 250 Accuhaler (GlaxoSmithKline UK Ltd) en Synonym Active Only initial character case insensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Seretide 250 Accuhaler (GlaxoSmithKline) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Is a Salmeterol+fluticasone propionate 50micrograms/250micrograms breath-actuated dry powder inhaler false Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has excipient Lactose false Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has active ingredient Salmeterol xinafoate true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has active ingredient Salmeterol false Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has active ingredient Fluticasone propionate true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has active ingredient Fluticasone false Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) VMP prescribing status (attribute) Caution - AMP level prescribing advised true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Is a Fluticasone propionate 250micrograms/dose / Salmeterol 50micrograms/dose dry powder inhaler true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) VMP prescribing status (attribute) VMP valid as a prescribable product false Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) VMP non-availability indicator Available false Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has manufactured dose form Conventional release powder for inhalation false Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Is a Seretide Accuhaler true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Salmeterol true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has specific active ingredient Salmeterol xinafoate true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has specific active ingredient Fluticasone propionate true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has dispensed dose form Conventional release powder for inhalation true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has manufactured dose form Inhalation dosage form false Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Has basis of strength substance Salmeterol true Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) Is a Fluticasone propionate 250micrograms/dose / Salmeterol 50micrograms/dose dry powder inhaler false Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Seretide 250 Accuhaler (GlaxoSmithKline) 60 dose Is pack of False Seretide 250 Accuhaler (GlaxoSmithKline) Inferred relationship Existential restriction modifier
Seretide 250 Accuhaler (GlaxoSmithKline) 60 dose Has AMP True Seretide 250 Accuhaler (GlaxoSmithKline) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start